Skip to main content
Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Characterisation of a Tip60 Specific Inhibitor, NU9056, in Prostate Cancer

  • Kelly Coffey,

    Affiliation Solid Tumour Target Discovery Laboratory, Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom

  • Timothy J. Blackburn,

    Affiliations Drug Discovery and Imaging Group, Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom, Research and School of Chemistry, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom

  • Susan Cook,

    Affiliation Solid Tumour Target Discovery Laboratory, Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom

  • Bernard T. Golding,

    Affiliations Drug Discovery and Imaging Group, Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom, Research and School of Chemistry, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom

  • Roger J. Griffin,

    Affiliations Drug Discovery and Imaging Group, Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom, Research and School of Chemistry, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom

  • Ian R. Hardcastle,

    Affiliations Drug Discovery and Imaging Group, Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom, Research and School of Chemistry, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom

  • Lorraine Hewitt,

    Affiliation Solid Tumour Target Discovery Laboratory, Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom

  • Kety Huberman,

    Affiliation OSI Pharmaceuticals, Inc, Farmingdale, New York, United States of America

  • Hesta V. McNeill,

    Affiliation Solid Tumour Target Discovery Laboratory, Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom

  • David R. Newell,

    Affiliation Drug Discovery and Imaging Group, Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom

  • Celine Roche,

    Affiliations Drug Discovery and Imaging Group, Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom, Research and School of Chemistry, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom

  • Claudia A. Ryan-Munden,

    Affiliation Solid Tumour Target Discovery Laboratory, Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom

  • Anna Watson,

    Affiliations Drug Discovery and Imaging Group, Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom, Research and School of Chemistry, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom

  • Craig N. Robson

    c.n.robson@ncl.ac.uk

    Affiliation Solid Tumour Target Discovery Laboratory, Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom

Viewed

Cited

Saved

Discussed

Powered by Altmetric
Questions or concerns about usage data? Please let us know.